本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、公司本次实施的利润分配方案为：以股份总数504,248,738股为基数，向 全体股东每10股派发现金红利1.600000元（含税）。公司本次现金分红的总金额 = 实 际 参 与 分 配 的 股 本 ×分 配 比 例 =504,248,738 股 ×1.600000 元 ÷10 股 = 80,679,798.08元（含税）。自分配方案披露至实施期间公司股本总额未发生变化。 2、本次权益分派方案实施后，按公司总股本折算每股现金分红=本次实际现 金分红总额/公司总股本= 80,679,798.08/504,248,738=0.160000元。 证券代码：300294 证券简称：博雅生物 公告编号：2024-064 华润博雅生物制药集团股份有限公司 2024 年半年度权益分派实施公告 3、本次实施的权益分派方案与公司2024年第三次临时股东大会审议通过的 分配方案一致。 4、本次权益分派距离股东大会审议通过利润分配方案的时间未超过两个 月。 二、本次实施的利润分配及资本公积金转增股本方案 1、分配年度：2024 ...

华润博雅生物制药集团股份有限公司（以下简称公司）监事会于近日收到职 工代表监事饶振先生提交的《辞任报告》，饶振先生因个人原因，申请辞去公司 第八届监事会职工代表监事职务，辞任后饶振先生仍继续担任公司首席制造官、 制造中心总经理的职务。饶振先生原定任期至第八届监事会任期届满之日（即 2027 年 03 月 20 日）止。截至本公告日，饶振先生未持有本公司股票，不存在 应当履行而未履行的承诺事项。 二、关于公司补选职工代表监事的情况 鉴于饶振先生的辞任将导致公司监事会成员人数低于法定最低人数，为保 证公司监事会正常运行，根据《公司法》《深圳证券交易所上市公司自律监管指 引第 2 号—创业板上市公司规范运作》等法律法规、规范性文件及《公司章程》 的相关规定，公司于 2024 年 9 月 27 日召开第六届职工代表大会第九次会议，同 意选举闫前前女士（简历详见附件）为第八届监事会职工代表监事，任期自本次 职工代表大会选举通过之日起至第八届监事会任期届满时止。 三、备查文件 证券代码：300294 证券简称：博雅生物 公告编号：2024-063 华润博雅生物制药集团股份有限公司 关于职工代表监事辞任暨补选职工代表监事的 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-062 华润博雅生物制药集团股份有限公司 第八届监事会第六次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 三、备查文件 1、公司第八届监事会第六次会议决议。 特此公告。 华润博雅生物制药集团股份有限公司监事会 2024 年 9 月 11 日 华润博雅生物制药集团股份有限公司（以下简称公司）第八届监事会第六次 会议于 2024 年 9 月 11 日在公司二楼会议室以通讯表决的方式召开。根据《公司 章程》等相关规定，本次会议通知以口头或者电话等方式发出，并已及时送达各 位监事。会议应参加表决监事 3 人，实参加表决监事 3 人。经半数以上监事推举， 会议由监事周娇女士主持，公司部分高级管理人员列席了会议。本次会议符合《中 华人民共和国公司法》（以下简称《公司法》）《中华人民共和国证券法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规定。 二、监事会会议审议情况 1、审议通过《关于选 ...

北 京 大 成 律师 事 务所 关 于 华 润 博 雅 生物 制 药集 团 股份 有 限公 司 2024 年第 三 次 临 时 股 东大 会 的 法律意见书 召开本次股东大会的通知及提案内容，已于 2024 年 8 月 24 日在深圳证券交 易所官方网站、巨潮资讯网进行了公告。 www.dachenglaw.com 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16 层 16-21F, Tower B, Zhaotai International Center, 10 Chaoyangmen Nandajie, Chaoyang District, Beijing 100020, China Tel: 8610-58137799 Fax: 8610-58137733 法律意见书——博雅生物 2024 年第三次临时股东大会 北京大成律师事务所关于华润博雅生物制药集团股份有限 公司 2024 年第三次临时股东大会的法律意见书 致：华润博雅生物制药集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-061 华润博雅生物制药集团股份有限公司 2024 年第三次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东大会决议事项的参 与度，本次股东大会对中小投资者进行单独计票，中小投资者是指除上市公司董 事、监事、高级管理人员以及单独或者合计持有公司 5%以上股份的股东以外的 其他股东； 2、本次股东大会不存在增加、变更、否决议案的情况； 3、本次股东大会不存在变更前次股东大会决议的情况； 4、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 华润博雅生物制药集团股份有限公司(以下简称公司)2024 年第三次临时股 东大会通知已于 2024 年 8月 24 日在中国证券监督管理委员会指定信息披露网站 巨潮资讯网（www.cninfo.com.cn）以公告方式发出。会议于 2024 年 9 月 11 日在 江西省抚州市高新技术产业开发区惠泉路 333 号公司会议室以现场与网络投票 相结合的方式召开。本次股东 ...

Investment Rating - The report assigns a "Hold" rating to the company with a target price of RMB 33.79, indicating a potential upside of 3% from the current price of RMB 32.77 [1][12]. Core Insights - The company is focusing on enhancing its gross margin through a strategic shift towards blood products, which have shown stable growth driven by sales of PCC and factor VIII products. However, the outlook for non-blood products remains uncertain due to significant revenue declines in related segments [4][9]. - The report highlights a significant drop in revenue for the first half of 2024, primarily due to the divestiture of non-blood product businesses, but notes an improvement in gross margin to 67.03%, up 17.1 percentage points year-on-year [4][7]. - Revenue forecasts for blood products are projected to grow at a compound annual growth rate (CAGR) of approximately 12.9% to 14.1% from 2024 to 2026, while non-blood product segments are expected to decline [4][11]. Summary by Sections Financial Performance - For 1H24, the company reported revenue of RMB 896 million, a decrease of 42% year-on-year, with a net profit of RMB 316 million, down 3% [7][9]. - The blood products segment generated RMB 790 million in revenue, reflecting a 3.6% increase year-on-year, while the biochemical drug segment saw a 45% decline [8][9]. Revenue and Profit Forecasts - The revenue forecast for 2024 has been adjusted downwards by 37% to RMB 1,887 million, with net profit estimates revised to RMB 597 million, reflecting a 2% increase from previous estimates [11][12]. - The earnings per share (EPS) for 2024 is projected at RMB 1.18, with subsequent years showing growth to RMB 1.35 in 2025 and RMB 1.51 in 2026 [11][12]. Valuation - The report employs a two-stage discounted cash flow (DCF) model for valuation, adjusting the weighted average cost of capital (WACC) to 8.7% and maintaining a perpetual growth rate of 1% [12][13]. - The target price of RMB 33.79 corresponds to a 2025 price-to-earnings (P/E) ratio of 25x, slightly above the average of comparable companies [12][14].

Investment Rating - The report maintains a "Buy" rating for the company [2][4][11]. Core Views - The company's performance in H1 2024 met expectations, with a revenue of 896 million yuan, a year-on-year decrease of 41.87%, and a net profit of 316 million yuan, down 3.05% year-on-year. The adjusted net profit increased by 0.57% year-on-year to 259 million yuan, with an EPS of 0.63 yuan [2]. - The blood products business showed steady growth, with revenue of 790 million yuan in H1 2024, a year-on-year increase of 3.64%. However, net profit from this segment decreased by 42.22% due to last year's dividend income and a decline in investment income [2]. - The company has expanded its plasma collection stations, now totaling 16, with significant increases in plasma collection volume, which rose by 14.63% year-on-year to 246.89 tons [2]. - Ongoing R&D projects are progressing well, and the construction of an intelligent factory for blood products is underway, expected to significantly enhance processing capacity in the future [2]. Financial Forecast - The company is projected to achieve revenues of 1.903 billion yuan, 2.013 billion yuan, and 2.113 billion yuan for the years 2024, 2025, and 2026, respectively. Corresponding net profits are expected to be 554 million yuan, 607 million yuan, and 637 million yuan, with EPS of 1.10 yuan, 1.20 yuan, and 1.26 yuan [2][3][10]. - The P/E ratios for the same years are forecasted to be 29 times, 27 times, and 25 times [2][3][10]. Business Development - The company is accelerating the expansion of plasma collection stations through both organic growth and acquisitions, enhancing its core competitiveness in the blood products sector [2]. - The acquisition of Green Cross has significantly boosted the company's plasma collection capacity, with an increase in collection volume from 104 tons in 2023 to 52.1 tons in H1 2024 [2]. R&D and Innovation - The company is actively advancing its R&D projects, including C1 esterase, vWF factor, and high-concentration intravenous immunoglobulin, which are expected to create a strong product pipeline [2]. - The intelligent factory project for blood products is progressing steadily, which is anticipated to greatly improve processing capabilities in the future [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company's performance in H1 2024 met expectations, with revenue of 896 million yuan (down 41.87%) and net profit of 316 million yuan (down 3.05%). The second quarter alone saw revenue of 447 million yuan (down 39.14%) and net profit of 164 million yuan (up 5.36%) [6] - The blood products business showed steady growth, achieving revenue of 790 million yuan (up 3.64%) in H1 2024, despite a decline in net profit due to last year's high dividend income and decreased investment returns [6] - The company is actively expanding its plasma collection resources, with a 14.63% increase in plasma collection volume to 246.89 tons in H1 2024. New licenses for plasma collection stations are expected to contribute additional revenue [6] - The R&D pipeline is progressing, with increased investment in innovation and several products nearing market readiness, including high-concentration immunoglobulin and other therapeutic agents [7] - The company forecasts revenues of 2.108 billion yuan, 2.387 billion yuan, and 2.679 billion yuan for 2024, 2025, and 2026 respectively, with corresponding net profits of 661 million yuan, 780 million yuan, and 910 million yuan [7] Summary by Sections Financial Performance - In H1 2024, the company reported a revenue of 896 million yuan, a decrease of 41.87%, and a net profit of 316 million yuan, down 3.05%. The gross margin improved to 67.03%, up 17.14 percentage points, while the net profit margin reached 35.25%, up 13.66 percentage points [6] - The blood products segment generated 790 million yuan in revenue, with specific products like human albumin and immunoglobulin showing varied performance [6] Business Expansion - The company has 14 operational plasma collection stations, with plans to expand further through new licenses and acquisitions, enhancing its competitive edge in raw plasma supply [6] Research and Development - R&D investment in H1 2024 was 43.78 million yuan, representing a 3.39% R&D expense ratio. The company is advancing its product pipeline with several candidates in clinical trials [7] Earnings Forecast - The company projects significant revenue growth from 2024 to 2026, with expected EPS of 1.31, 1.55, and 1.81 yuan, and corresponding P/E ratios of 24.48, 20.75, and 17.78 [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a significant increase in non-recurring profit in Q2, indicating a promising outlook for tonnage profit [1] - The company achieved a revenue of 896 million yuan in H1 2024, a year-on-year decrease of 41.87%, while the net profit attributable to shareholders was 316 million yuan, a decrease of 3.05% [1] - The company’s gross margin improved significantly to 67.03% in H1 2024, an increase of 17.14 percentage points year-on-year [1] - The blood products business showed steady growth, with revenue reaching 790 million yuan in H1 2024, a year-on-year increase of 3.64% [1] - The company has expanded its plasma collection capacity through strategic acquisitions, which is expected to enhance its core competitiveness [3] Financial Summary - For 2024, the company is projected to generate revenues of 1.971 billion yuan, a year-on-year decrease of 25.7%, with net profits expected to reach 557 million yuan, reflecting a significant increase of 134.7% [4][3] - The gross margin is expected to rise to 70.9% in 2024, with a gradual increase projected through 2026 [4] - The company’s operating cash flow for 2024 is estimated at 863 million yuan, indicating a strong cash generation capability [5] - The company’s total assets are projected to grow from 7.829 billion yuan in 2023 to 9.449 billion yuan by 2026 [6] Business Outlook - The company is expected to see a gradual recovery in revenue growth from 2025 onwards, with projected revenues of 2.136 billion yuan in 2025 and 2.289 billion yuan in 2026, reflecting year-on-year growth rates of 8.3% and 7.2% respectively [3] - The strategic acquisition of Green Cross is anticipated to further enhance the company’s plasma collection capabilities and overall performance [3][1]

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company's blood products revenue is steadily increasing, with a notable performance from new products [2]. - The acquisition of Green Cross is expected to enhance the company's competitive edge in the blood products industry [2]. - The company is investing heavily in R&D, which is expected to optimize its product structure and strengthen its core competitiveness [2]. Summary by Relevant Sections Financial Performance - In H1 2024, the company achieved revenue of 896 million yuan, a year-on-year decrease of 41.87%, while the net profit attributable to the parent company was 316 million yuan, down 3.05% [1]. - The blood products business generated revenue of 790 million yuan, an increase of 3.64% year-on-year, with net profit of 319 million yuan, a decrease of 42.22% [2]. - The company’s R&D investment for H1 2024 was 438 million yuan, representing a 3.39% R&D expense ratio [2]. Product Performance - Human albumin generated revenue of 233 million yuan, up 3.84% year-on-year; intravenous immunoglobulin revenue was 220 million yuan, down 14.27%; and fibrinogen revenue was 208 million yuan, down 1.64% [2]. Acquisition and Market Position - The acquisition of Green Cross is expected to significantly increase the scale of raw plasma collection, with the company currently operating 16 plasma collection stations [2]. - The company collected 246.89 tons of raw plasma in H1 2024, a year-on-year increase of 14.63% [2]. Earnings Forecast and Valuation - The forecast for net profit attributable to the parent company for 2024-2026 is 551 million, 602 million, and 656 million yuan, respectively, with year-on-year growth rates of 132.11%, 9.26%, and 9.00% [2]. - The estimated EPS for 2024-2026 is 1.09, 1.19, and 1.30 yuan, with corresponding P/E ratios of 29, 27, and 25 times [2].